Annual Report

Overview

The report highlights consolidated net sales of ¥282,904 million and record operating income in fiscal 2012. It describes the Group's globalization, including the US launch of Osphena as its first global drug. CSR disclosures cover employee health initiatives, ISO 14001 certification, and a 6.8% reduction in CO2 emissions against the benchmark fiscal year.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2012-2013
Period: 1 April 2012 – 31 March 2013
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services